Edge Therapeutics Now Covered by Leerink Swann (EDGE)

Leerink Swann initiated coverage on shares of Edge Therapeutics (NASDAQ:EDGE) in a report published on Monday, The Fly reports. The firm issued an outperform rating and a $27.00 price target on the stock.
Separately, Credit Suisse began coverage on shares of Edge Therapeutics in a research report on Monday. They issued an outperform rating and a $29.00 price target on the stock.

This entry was posted in Recent Development News: Q4 - 2015, Recent Developments. Bookmark the permalink.
Read Full Article »